NASDAQ:AMED - Amedisys Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $136.22 -2.51 (-1.81 %) (As of 02/17/2019 03:40 PM ET)Previous Close$136.22Today's Range$134.49 - $136.7652-Week Range$55.41 - $140.91Volume698,499 shsAverage Volume326,981 shsMarket Capitalization$4.34 billionP/E Ratio61.64Dividend YieldN/ABeta1.43 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana. Receive AMED News and Ratings via Email Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED Previous Symbol CUSIP02343610 Webwww.amedisys.com Phone225-292-2031Debt Debt-to-Equity Ratio0.12 Current Ratio1.06 Quick Ratio1.06Price-To-Earnings Trailing P/E Ratio61.64 Forward P/E Ratio38.05 P/E Growth1.81 Sales & Book Value Annual Sales$1.53 billion Price / Sales2.83 Cash Flow$2.7480 per share Price / Cash Flow49.57 Book Value$15.22 per share Price / Book8.95Profitability EPS (Most Recent Fiscal Year)$2.21 Net Income$30.30 million Net Margins5.39% Return on Equity23.27% Return on Assets14.26%Miscellaneous Employees17,900 Outstanding Shares31,889,000Market Cap$4.34 billion OptionableOptionable Amedisys (NASDAQ:AMED) Frequently Asked Questions What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." How were Amedisys' earnings last quarter? Amedisys Inc (NASDAQ:AMED) posted its earnings results on Monday, October, 29th. The health services provider reported $0.95 EPS for the quarter, topping the Zacks' consensus estimate of $0.77 by $0.18. The health services provider earned $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The company's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.56 EPS. View Amedisys' Earnings History. When is Amedisys' next earnings date? Amedisys is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Amedisys. What price target have analysts set for AMED? 13 brokerages have issued 1 year price targets for Amedisys' shares. Their forecasts range from $63.00 to $139.00. On average, they expect Amedisys' share price to reach $111.8185 in the next twelve months. This suggests that the stock has a possible downside of 17.9%. View Analyst Price Targets for Amedisys. What is the consensus analysts' recommendation for Amedisys? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedisys. Has Amedisys been receiving favorable news coverage? News coverage about AMED stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amedisys earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the health services provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Amedisys' key competitors? Some companies that are related to Amedisys include Chemed (CHE), LHC Group (LHCG), Addus Homecare (ADUS), Civitas Solutions (CIVI), BioScrip (BIOS) and New York Health Care (BBAL). Who are Amedisys' key executives? Amedisys' management team includes the folowing people: Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)Mr. Scott G. Ginn, Chief Financial Officer (Age 50)Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)Mr. Michael P. North, Chief Information Officer (Age 54)Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems Who are Amedisys' major shareholders? Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.74%), Dimensional Fund Advisors LP (3.14%), Acadian Asset Management LLC (2.52%), Bank of New York Mellon Corp (1.62%), Geode Capital Management LLC (1.35%) and Northern Trust Corp (1.20%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Linda J Hall, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys. Which major investors are selling Amedisys stock? AMED stock was sold by a variety of institutional investors in the last quarter, including Kohlberg Kravis Roberts & Co. L.P., Northern Trust Corp, Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Castleark Management LLC, Hancock Whitney Corp, First Trust Advisors LP and TD Asset Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys. Which major investors are buying Amedisys stock? AMED stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Acadian Asset Management LLC, Millennium Management LLC, Robeco Institutional Asset Management B.V., Geode Capital Management LLC, Bank of America Corp DE, Columbus Circle Investors and Meritage Portfolio Management. View Insider Buying and Selling for Amedisys. How do I buy shares of Amedisys? Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $136.22. How big of a company is Amedisys? Amedisys has a market capitalization of $4.34 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe. What is Amedisys' official website? The official website for Amedisys is http://www.amedisys.com. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected] MarketBeat Community Rating for Amedisys (NASDAQ AMED)Community Ranking: 1.9 out of 5 ()Outperform Votes: 285 (Vote Outperform)Underperform Votes: 450 (Vote Underperform)Total Votes: 735MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: What are Bollinger Bands?